Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma-Reference-Cited by-同舟云学术

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

Published:2018-09-25 Issue:7 Volume:26 Page:1267-1282
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Fattore Luigi,Ruggiero Ciro Francesco,Pisanu Maria Elena,Liguoro Domenico,Cerri Andrea,Costantini Susan,Capone Francesca,Acunzo Mario,Romano Giulia,Nigita Giovanni,Mallardo Domenico,Ragone Concetta,Carriero Maria Vincenza,Budillon Alfredo,Botti Gerardo,Ascierto Paolo Antonio^ORCID,Mancini Rita,Ciliberto Gennaro^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41418-018-0205-5.pdf

Reference50 articles.

1. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol. 2017;43:604–11.

2. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85–5876-10–85.

3. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: Where do we go next? Lancet Oncol. 2014;15:e371–81.